Financial Comparison: Xcorporeal (OTCMKTS:XCRP) vs. CVRx (NASDAQ:CVRX)

CVRx (NASDAQ:CVRX) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Profitability

This table compares CVRx and Xcorporeal’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Xcorporeal	N/A	N/A	N/A

Institutional & Insider Ownership

75.3% of CVRx shares are owned by institutional investors. 13.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CVRx and Xcorporeal, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1	0	1	1	2.67
Xcorporeal	0	0	0	0	0.00

CVRx presently has a consensus target price of $11.50, indicating a potential upside of 134.22%. Given CVRx’s stronger consensus rating and higher possible upside, equities analysts clearly believe CVRx is more favorable than Xcorporeal.

Valuation & Earnings

This table compares CVRx and Xcorporeal”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65 million	2.30	-$53.31 million	($2.02)	-2.43
Xcorporeal	N/A	N/A	N/A	N/A	N/A

Xcorporeal has lower revenue, but higher earnings than CVRx.

Summary

CVRx beats Xcorporeal on 7 of the 10 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.